The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae.
There is a pressing need for a gonorrhea vaccine due to the high disease burden associated with gonococcal infections globally and the rapid evolution of antibiotic resistance in Neisseria gonorrhoeae (Ng). Current gonorrhea vaccine research is in the stages of antigen discovery and the identificati...
Main Authors: | Isabelle Leduc, Kristie L Connolly, Afrin Begum, Knashka Underwood, Stephen Darnell, William M Shafer, Jacqueline T Balthazar, Andrew N Macintyre, Gregory D Sempowski, Joseph A Duncan, Marguerite B Little, Nazia Rahman, Eric C Garges, Ann E Jerse |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-12-01
|
Series: | PLoS Pathogens |
Online Access: | https://doi.org/10.1371/journal.ppat.1008602 |
Similar Items
-
Evolution of strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in France
by: Eva Hong, et al.
Published: (2021-12-01) -
Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review
by: Véronique Abitbol, et al.
Published: (2023-08-01) -
Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland
by: Margherita Bodini, et al.
Published: (2020-10-01) -
Meningococcal B Vaccination (4CMenB) in Infants and Toddlers
by: Susanna Esposito, et al.
Published: (2015-01-01) -
Progressive decrease in the potential usefulness of meningococcal serogroup B vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain.
by: Emilio Pérez-Trallero, et al.
Published: (2014-01-01)